Revenue and Profit Growth
Rossari Biotech's net sales have shown a remarkable upward trend, rising from ₹600.09 crores in March 2020 to ₹2,080.29 crores by March 2025. This more than threefold increase over five years underscores the company's expanding market presence and product demand. Correspondingly, the total operating income mirrored this growth, reflecting the absence of other operating income during this period.
Profitability metrics have also improved significantly. The consolidated net profit increased from ₹65.25 crores in March 2020 to ₹136.38 crores in March 2025, nearly doubling in size. Earnings per share (EPS) followed suit, climbing from ₹12.86 to ₹24.64, indicating enhanced returns for shareholders. Despite this growth, the profit after tax (PAT) margin experienced some compression, declining from 10.87% in 2020 to 6.56% in 2025, suggesting rising costs or competitive pressures impacting net margins.
Operating profit (PBDIT) excluding other income rose steadily from ₹104.74 crores in March 2020 to ₹265.07 crores in March 2025, reflecting operational efficiency gains and scale benefits. However, operating profit margins narrowed from 17.45% to 12.74% over the same period, consistent with the PAT margin trend.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Cost Structure and Expenditure
The company's raw material costs have risen in line with sales, from ₹369.26 crores in 2020 to ₹1,299.64 crores in 2025, reflecting increased production volumes and input prices. Purchase of finished goods also increased, indicating a strategic mix of in-house manufacturing and procurement. Employee costs more than tripled, from ₹37.21 crores to ₹132.33 crores, signalling investment in human capital to support growth.
Other expenses have similarly escalated, reaching ₹249.59 crores in 2025 from ₹86.44 crores in 2020, which may include marketing, administrative, and other operational costs. Despite these rising expenses, the company has maintained positive operating leverage, as evidenced by the growth in absolute operating profits.
Balance Sheet Strength and Capital Structure
Rossari Biotech's total assets expanded substantially from ₹471.46 crores in 2020 to ₹1,885.67 crores in 2025, driven by increases in net block, capital work in progress, and current assets. Shareholder's funds more than quadrupled, reaching ₹1,185.45 crores, supported by rising reserves and retained earnings. Book value per share improved from ₹56.48 to ₹214.12, reflecting enhanced net worth per share.
The company’s debt profile shows a rise in total debt from ₹61.01 crores in 2020 to ₹187.97 crores in 2025, with long-term borrowings increasing notably in recent years. This suggests a measured use of leverage to finance expansion. Current liabilities also grew, consistent with the company's larger scale of operations.
Cash Flow and Liquidity
Cash flow from operating activities has fluctuated but generally trended upwards, with ₹137 crores generated in 2025 compared to ₹56 crores in 2020. Investing activities have consistently been cash outflows, reflecting ongoing capital expenditure and investments in growth. Financing activities have varied, with inflows in recent years supporting capital needs. The net cash inflow in 2025 was ₹19 crores, improving liquidity and cash reserves, which stood at ₹44 crores at year-end.
Rossari Biotech or something better? Our SwitchER feature analyzes this Smallcap Specialty Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary and Investor Takeaways
Over the last six fiscal years, Rossari Biotech has exhibited a strong and consistent growth pattern in revenue and profitability, supported by expanding operational scale and improving shareholder equity. While margins have compressed somewhat, the company’s ability to grow absolute profits and maintain positive cash flows from operations is a positive indicator of financial health. The measured increase in debt to fund expansion appears manageable given the growth in assets and equity.
Investors seeking exposure to a growing specialty chemicals company with a track record of scaling operations and enhancing shareholder value may find Rossari Biotech’s historical performance encouraging. However, attention should be paid to margin trends and cost management going forward to sustain profitability in a competitive environment.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
